Copyright © Inderes 2011 - present. All rights reserved.
Regulatoriskt pressmeddelande

Interim report January – September 2024: 12% CURRENCY-NEUTRAL INCREASE IN SALES

Surgical Science Sweden
Ladda ner börsmeddelandet

THIRD QUARTER 2024 (JUL – SEP)

Net sales amounted to SEK 231.8 (210.2) million, an increase of 10 percent compared with the corresponding period in the preceding year.

License revenue amounted to SEK 65.0 (55.5) million and accounted for 28 (26) percent of net sales.

The gross margin was 69 (69) percent.

Operating profit amounted to SEK 45.8 (50.7) million.

Net profit amounted to SEK 43.0 (47.4) million, corresponding to earnings per share of SEK 0.84 (0.93).

Cash flow from operating activities amounted to SEK 22.1 (53.1) million. As at September 30, 2024, cash and cash equivalents amounted to SEK 666.3 (606.1) million.

FIRST NINE MONTHS OF 2024 (JAN – SEP)

Net sales amounted to SEK 632.5 (655.6) million, a decrease of 4 percent compared with the preceding year.

License revenue amounted to SEK 195.3 (201.8) million and accounted for 31 (31) percent of net sales.

The gross margin was 68 (69) percent.

Operating profit amounted to SEK 105.2 (151.5) million.

Net profit amounted to SEK 95.4 (136.0) million, corresponding to earnings per share of SEK 1.87 (2.67).

Cash flow from operating activities amounted to SEK 80.6 (198.7) million.

Gothenburg, Sweden, November 14, 2024
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 270 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-14 07:30 CET.

Attachments

241114 Q32024 ENG

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.